Cure8 research brief
Early, noninvasive biomarkers could help detect ulcerative colitis and related colorectal cancer risk sooner. This study identifies four serum-accessible proteins with promising diagnostic accuracy in the reported cohorts.
Researchers, clinicians focused on IBD/colorectal cancer diagnostics, and patients interested in emerging noninvasive tests
Researchers used DIA mass spectrometry on paired colorectal tissue and exudate samples, then validated four candidate proteins by ELISA in serum. The study found pathway shifts (oxidative phosphorylation to glycolysis), immune-related changes, and extracellular matrix remodeling, and reports AUCs for the four markers in UC and CRC comparisons.
The article presents these proteins as promising serum biomarkers but does not report prospective clinical validation or how they perform in routine screening outside the study cohorts.
This is an abstract-level report of a proteomics discovery and initial validation study. It does not replace prospective clinical testing or guideline-backed screening methods.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with long-standing ulcerative colitis face an increased risk of colorectal cancer; this study highlights PPARGC1A as a gene that may be downregulated early in that progression, which could eventually help identify...
Intestinal fibrosis is a serious complication of long-standing ulcerative colitis. Identifying NET-related biomarkers (IL1RN, MUC1, SERPINA1) could help researchers develop better diagnostic tools or treatments targeting...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
